Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 17

Pertuzumab
A mechanism of action designed to bind to the
HER dimerisation domain
By targeting HER2, the preferred pairing partner for
HER1, HER3 and HER4, pertuzumab may
inhibit
multiple HER signaling pathways
AKT
PDK1
cell cycle
control
apoptosis
survival
Cyclin D1
p27
BAD
GSK3
NF
B
mTOR
P P P P P
proliferation
angiogenesis
P13K
HER3
HER2
Trastuzumab
Pertuzumab: A HER dimerisation
inhibitor
Pertuzumab
1...,7,8,9,10,11,12,13,14,15,16 18,19,20,21,22,23,24,25,26,27,...47
Powered by FlippingBook